Page 47 - MBCA_FULL REPORT_FINAL_FOR_WEB

As seen in Figure 7, the MBC Grants Dataset was composed predominantly of basic research
grants (69%), 24% represented translational research, and vastly smaller percentages were grants
for clinical research (6%) and cancer control research (1%). These percentages did not vary
substantially across the time studied.

Only 41 grants in the MBC Grants Dataset were related to MBC Figure 7: Stages of Research in the MBC
survivorship and outcomes research (includes projects both Research Grants from 2000–2013
wholly and partly related to survivorship and outcomes
research). A review of these grants revealed that they are 100% CANCER CONTROL: 1-2%
focused on bone pain, behavioral–psychological factors, and
treatment side effects relevant to MBC. CLINICAL 5-9%
6% avg.
Information on the molecular targets, cellular pathways, and
therapies being studied was also extracted and captured TRANSLATIONAL 22-26%
from the MBC Grants Dataset. As Appendix 3 shows, a wide 24% avg.
range of molecular targets are being pursued (estimated at
>200).The most common targets in those projects with a
clinical focus are ErbB/HER, vascular endothelial growth factor
(VEGF) pathway family, bone/osteolysis pathways, hormone
receptors, and immune system (general). BASIC 66-72%
69% avg.

50%

0%
2000 – 2013

47